Physician profile
Ann Marie King
NPI 1104401157
$2,202.51
in general payments reported to CMS, 2019-2025
29 companies · $15.79 in 2025
The $15.79 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,128 · 2022: $29.38 · 2024: $29.40 · 2025: $15.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $45.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $45.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $171.66 | 2021 | |
| Novartis Pharmaceuticals Corporation | $169.39 | 2021 | |
| Acadia Pharmaceuticals INC | $157.39 | 2021 | |
| Allergan, INC. | $150.61 | 2021-2022 | |
| Abbvie INC. | $143.67 | 2021-2024 | |
| Biohaven Pharmaceuticals, INC. | $133.57 | 2021 | |
| Ucb, INC. | $133.19 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $101.48 | 2021 | |
| Lilly USA, LLC | $99.39 | 2021 | |
| Alexion Pharmaceuticals, INC. | $95.26 | 2021 | |
| Sk Life Science, INC. | $94.82 | 2021 | |
| Merz Pharmaceuticals, LLC | $91.47 | 2021 | |
| Lundbeck LLC | $71.60 | 2021 | |
| Genzyme Corporation | $61.36 | 2021 | |
| Amgen INC. | $57.52 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $55.01 | 2021 | |
| Jazz Pharmaceuticals INC. | $54.88 | 2021 | |
| Acorda Therapeutics, INC | $46.75 | 2021 | |
| Sunovion Pharmaceuticals INC. | $40.91 | 2021 | |
| Csl Behring | $40.00 | 2021 | |
| Tanabe Pharma America, INC. | $39.90 | 2021 | |
| Mallinckrodt Hospital Products INC. | $39.44 | 2021 | |
| Sobi, INC | $38.48 | 2021 | |
| Grifols USA, LLC | $35.48 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $20.60 | 2021 | |
| Celgene Corporation | $16.27 | 2021 | |
| Polynovo North America LLC | $15.79 | 2025 | Novosorb Btm |
| Janssen Pharmaceuticals, INC | $13.93 | 2021 | |
| Supernus Pharmaceuticals, INC. | $12.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.